The application of Efgartigimod in this case also yielded remarkable efficacy, suggesting that FcRn blockade is not only effective in managing MG crises but may also help alleviate antibody-mediated immune responses in ICI-associated myocarditis, offering a new therapeutic direction for such complex immune toxicities. The gene discussed is FCGRT; the disease is myasthenia gravis.